Effectiveness analyses may underestimate protection of infants after group C meningococcal immunization

J Infect Dis. 2006 Jul 15;194(2):231-7. doi: 10.1086/505077. Epub 2006 Jun 13.

Abstract

Background: Group C meningococcal conjugate-vaccine effectiveness in the United Kingdom declines from ~90% in the first year to 0% between 1 and 4 years after immunization in infants immunized at 2, 3, and 4 months of age and to 61% in toddlers given a single dose. Confidence intervals are wide, and the extent of protection is uncertain.

Methods: Serum samples were obtained from children 3-5 years of age who were participants in a preschool booster-vaccine trial. Serum bactericidal activity was measured with human complement. Group C anticapsular antibody concentrations were measured by a radioantigen binding assay. Passive protection was analyzed in an infant rat bacteremia model.

Results: Serum samples from UK children who had been immunized 2-3 years earlier as infants or toddlers had higher levels of radioantigen binding, bactericidal activity, and passive protection than did historical control serum samples from unimmunized children (P<.05). A higher proportion of children immunized as infants had serum bactericidal activity titers > or =1 : 4 (considered to be protective) than those immunized as toddlers (61% vs. 24%; P<.01), but there were no significant differences in the proportion of serum samples conferring passive protection (50% and 41%, respectively; P=.4).

Conclusions: We found no evidence of lower immunity in children immunized as infants than as toddlers. On the basis of serum bactericidal activity and/or passive protection, 40%-50% of both age groups are protected at 2-3 years after immunization, which was significantly greater than in unimmunized historical controls (<5%).

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Antibodies, Bacterial / blood
  • Child, Preschool
  • England
  • Humans
  • Immunization, Secondary*
  • Meningitis, Meningococcal / immunology
  • Meningitis, Meningococcal / prevention & control*
  • Meningococcal Vaccines / administration & dosage*
  • Meningococcal Vaccines / immunology*
  • Neisseria meningitidis, Serogroup C / immunology*

Substances

  • Antibodies, Bacterial
  • Meningococcal Vaccines